Press Release

Ref: ADL/SE/2026-27/58 November 3, 2026 To, To, Listing/ Compliance Department Listing/ Compliance Department BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, “Exchange Plaza”, Plot No. C/1, Dalal Street, G Block Bandra - Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai – 400051 BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS Dear Sir/Madam, Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sub: Press Release on Financial Results. Please find attached herewith press release on Financial Results for the Quarter and half year ended September 30, 2026. Kindly take the same on record. Thanking you, Yours faithfully, FOR AARTI DRUGS LIMITED RUSHIKESH DEOLE COMPANY SECRETARY & COMPLIANCE OFFICER ICSI M. No.: F12932 Investor Release Q2 & H1FY27 Business & Financial Performance Mumbai, 3rd November 2026 Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS; BSE:524348), a Mumbai based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API), Formulation, Specialty Chemicals and Intermediates announced its unaudited Financial Results for the Quarter and Half year ended 30th September 2026. Consolidated Financial Highlights Particulars (Rs. Crs.)1 Q2 FY27 Q2 FY26 YoY% Q1 FY27 QoQ% H1 FY27 H1 FY26 YoY% Total Revenue 828.8 652.9 27% 703.6 18% 1,532.4 1,243.7 23% Gross Profit 329.7 244.6 35% 276.0 19% 605.7 462.0 31% EBITDA 137.9 84.4 63% 96.9 42% 234.8 158.8 48% EBITDA Margin% 16.6% 12.9% 370 bps 13.8% 280 bps 15.3% 12.8% 250 bps Profit After Tax (PAT) 82.8 45.2 83% 50.1 65% 132.9 99.1 34% PAT Margin% 10.0% 6.9% 310 bps 7.1% 290 bps 8.7% 8.0% 70 bps EPS (in Rs.) 9.07 4.95 83% 5.49 65% 14.56 10.86 34% 1 All figures include Other Income Consolidated Financial Highlights – Q2 FY27 • Revenue stood at Rs. 828.8 crore as compared to Rs. 652.9 crore in Q2 FY26, reflecting a growth of 27% YoY • EBITDA stood at Rs. 137.9 crore versus Rs. 84.4 crore in Q2 FY26, recording a growth of 63% YoY. EBITDA margin stood at 16.6%, an expansion of 370 bps YoY • PAT stood at Rs. 82.8 crore as compared to Rs. 45.2 crore in Q2 FY26, a growth of 83% YoY. PAT margin stood at 10.0%, an expansion of 310 bps YoY Consolidated Financial Highlights – H1 FY27 • Revenue stood at Rs. 1,532.4 crore as compared to Rs. 1,243.7 crore in H1 FY26, reflecting a growth of 23% YoY • EBITDA stood at Rs. 234.8 crore versus Rs. 158.8 crore in H1 FY26, recording a growth of 48% YoY. EBITDA margin stood at 15.3%, an expansion of 250 bps YoY • PAT stood at Rs. 132.9 crore as compared to Rs. 99.1 crore in H1 FY26, a growth of 34% YoY. PAT margin stood at 8.7%, an expansion of 70 bps YoY Segmental Performance Update Particulars (Rs. Crs.) Q2 FY27 Q2 FY26 YoY% Q1 FY27 QoQ% H1 FY27 H1 FY26 YoY% API 604.5 515.9 17% 510.4 18% 1,115.0 974.1 14% Formulation 130.0 82.4 58% 86.2 51% 216.3 162.8 33% Specialty Chemicals 71.8 37.3 92% 82.6 -13% 154.3 70.4 119% Intermediates & Others 19.9 17.1 16% 23.5 -15% 43.4 36.1 20% Investor Release Standalone4 Business Highlights – Q2 FY27 • Revenue stood at Rs. 708.9 crores vs. Rs. 579.0 crores in Q2 FY26, a growth of 22% YoY • Standalone business contributed 86% to the consolidated revenue • 68% of the standalone revenue came from the domestic market and 32% from the exports market • Domestic revenue grew 43% YoY, while export revenue declined by 5% YoY • Within the API business, the anti-biotic therapeutic category contributed 34.1%, anti-protozoal 18.1%, anti-inflammatory 14.8%, anti-diabetic 18.2%, antifungal 9.3% and the rest contributed 5.6% to total API sales Formulation4 Segment Highlights • Revenue from formulations in Q2 FY27 stood at Rs. 130.0 crore compared to Rs. 82.5 crore in Q2 FY26, up 58% YoY. Exports contributed 74% to this revenue • For H1 FY27, formulation revenue stood at Rs. 211.7 crore compared to Rs. 162.8 crore in H1 FY26, up 30%, with exports accounting for 63% of total formulation sales 4 Includes other income Commenting on the same, Mr. Adhish Patil, Managing Director, Aarti Drugs Limited said, “Q2 FY27 has been a landmark quarter for Aarti Drugs. We achieved our highest-ever revenue from operations of Rs. 826 crore and reported our highest-ever quarterly EBITDA of Rs. 138 crore. EBITDA margin expanded 370 basis points to 16.6%, the highest level in nearly six years. This performance reflects a combination of volume growth, strong realisations across our API, formulations and Specialty Chemicals portfolio, and the steady progress we have made in building a more integrated manufacturing platform. Through a period of considerable global volatility, all our facilities operated without disruption which enabled us to serve our customers reliably as their trusted partner. Growth during the quarter was broad-based across our businesses. Our Specialty Chemicals business nearly doubled as our Sayakha facility scaled up, and our Formulations business grew 58%, led by strong demand in export markets. Within a year of commissioning, Sayakha is meeting a significant share of our metformin intermediate requirements in-house, enhancing both our cost competitiveness and the security of our supply chain in the anti-diabetic segment. At the same time, our capacity expansions at Tarapur, Sarigam and Baddi, including new USFDA-compliant capacity, are progressing well and will deepen our presence in regulated markets. This period also marks an important moment in our leadership journey. Starting October 1st 2026, Mr. Prakash M. Patil retired as Chairman, Managing Director and CEO after a lifetime of dedicated service to the Company. His vision, integrity and leadership laid the foundations on which Aarti Drugs stands today, and on behalf of the Board and the entire Aarti Drugs family, I express our deepest gratitude to him. With Mr. Rashesh Gogri taking over as Chairman, and as I take charge as Managing Director, we remain committed to the values and long-term thinking that have guided the Company for decades. Looking ahead, we are building Aarti Drugs into a more integrated, more diversified and more globally relevant pharmaceutical company and aim to remain focused on improving capacity utilisation, expanding our regulatory footprint and creating sustainable growth for all our stakeholders.” Investor Release About Aarti Drugs Limited Aarti Drugs Limited was established in the year 1984 and forms part of $6 Billion Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and produces Formulations with its wholly- owned subsidiary-Pinnacle Life Science Private Limited. The Company have total 14 manufacturing facilities out of which 10 manufacturing facilities are in Maharashtra, 3 Manufacturing facilities in Gujarat and 1 Manufacturing facility of Pinnacle is located at Himachal Pradesh. Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc. For more information, please visit http://www.aartidrugs.com/ Safe Harbor Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assu [Showing first 8,000 characters — download PDF for full document]